What is Protalix BioTherapeutics, Inc.'s earnings per share (EPS)?

Protalix BioTherapeutics, Inc. (PLX) reported diluted earnings per share of -$0.08 for fiscal year 2025. This represents a -300.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Protalix BioTherapeutics, Inc. (PLX) Financials

PLX

Trailing 12 months to June 30, 2026

Revenue $80.6M +30.1% YoY

Net Income $18.9M +201.9% YoY

EPS (Diluted) $0.23 +228.6% YoY

Free Cash Flow $7.7M +322.6% YoY

Market Cap $224.0M as of Oct 12, 2026

Price / Sales 2.8x on $80.6M revenue, trailing 12 months to June 30, 2026

Price / Earnings 11.8x on $18.9M net income, trailing 12 months to June 30, 2026

Price / Book 3.1x on $71.4M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 12, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PLX SEC filings page.

Protalix BioTherapeutics, Inc. (PLX) reported $80.6M in revenue over the twelve months to Jun 30, 2026, up 30.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PLX FY2025 2026-10-03

Profitability has been intermittent: FY2025’s margin reversal and cash outflow followed FY2024 improvement, while liquidity remained current-asset heavy.

FY2025 reversed FY2024’s operating improvement: operating margin went from 7.3% to -10.4%. Gross-margin compression and the shift from positive to negative operating cash flow indicate the weaker earnings period reached the cash ledger, rather than being only an accounting effect.

The balance sheet now has positive equity of $48.2M and a reported debt-to-equity ratio of 0.7x; that is a materially different financing posture from the negative-equity years. Current ratio reached 2.5x, yet inventory climbed to $25.7M; the liquidity cushion is increasingly tied to converting operating assets into cash.

R&D investment rose to $19.6M even as revenue was nearly flat, so FY2025’s loss reflects a renewed investment burden more than a top-line collapse. Operating cash flow of -$12.0M was paired with $9.3M of financing cash flow, showing that reported cash needs were partly met through financing rather than operations.

Financial Health Signals

Financial Health Score 39/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Protalix BioTherapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Protalix BioTherapeutics, Inc. held $14.7M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $12.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Protalix BioTherapeutics, Inc. scores 38/100 among other emerging companies.

Dilution

Protalix BioTherapeutics, Inc. had 81M shares outstanding at the end of fiscal year 2025, against 78M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Protalix BioTherapeutics, Inc. scores 57/100 among other emerging companies.

R&D Intensity

Protalix BioTherapeutics, Inc. spent $19.6M on research and development in fiscal year 2025, which was 33.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Protalix BioTherapeutics, Inc. scores 66/100 among other emerging companies.

Revenue Progress

Protalix BioTherapeutics, Inc. reported revenue of $52.7M in fiscal year 2025, against $53.4M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Protalix BioTherapeutics, Inc. scores 30/100 among other emerging companies.

Burn Trend

Protalix BioTherapeutics, Inc.'s operations used $12.0M of cash in fiscal year 2025, against $8.7M generated in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Protalix BioTherapeutics, Inc. scores 4/100 among other emerging companies.

Balance Sheet

Protalix BioTherapeutics, Inc.'s cash, cash equivalents and investments came to $14.7M at the end of fiscal year 2025, against $34.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Protalix BioTherapeutics, Inc. scores 40/100 among other emerging companies.

Altman Z-Score Distress

-1.60

Protalix BioTherapeutics, Inc. scores -1.60, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($224.0M) relative to total liabilities ($34.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/8

Protalix BioTherapeutics, Inc. passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Protalix BioTherapeutics, Inc. reported a net loss of $6.6M while operations used $12.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$19.9M

YoY+27.1%

QoQ-41.0%

5Y CAGR+25.4%

10Y CAGR+27.4%

Protalix BioTherapeutics, Inc. generated $19.9M in revenue in Q2 2026. This represents an increase of 27.1% from the same quarter a year earlier. Against the prior quarter it is down 41.0%.

EBITDA

$5.1M

YoY+231.5%

QoQ-76.4%

Protalix BioTherapeutics, Inc.'s EBITDA was $5.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 231.5% from the same quarter a year earlier. Against the prior quarter it is down 76.4%.

Net Income

$3.8M

YoY+2203.0%

QoQ-79.4%

Protalix BioTherapeutics, Inc. reported $3.8M in net income in Q2 2026. This represents an increase of 2203.0% from the same quarter a year earlier. Against the prior quarter it is down 79.4%.

EPS (Diluted)

$0.05

QoQ-77.3%

Protalix BioTherapeutics, Inc. earned $0.05 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 77.3%.

Cash & Balance Sheet

Free Cash Flow

-$11.0M

YoY-94.1%

QoQ-151.7%

Protalix BioTherapeutics, Inc. recorded an outflow of $11.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 94.1% from the same quarter a year earlier. Against the prior quarter it is down 151.7%.

Cash & Debt

$27.4M

YoY+53.2%

QoQ-33.1%

5Y CAGR-4.1%

10Y CAGR-6.7%

Protalix BioTherapeutics, Inc. held $27.4M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

81M

YoY+1.1%

QoQ0.0%

5Y CAGR+12.1%

10Y CAGR-2.1%

Protalix BioTherapeutics, Inc. had 81M shares outstanding in Q2 2026. This represents an increase of 1.1% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

61.0%

YoY-1.5pp

QoQ-26.8pp

5Y change+34.6pp

10Y change+55.7pp

Protalix BioTherapeutics, Inc.'s gross margin was 61.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 1.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 26.8 percentage points.

Operating Margin

23.5%

YoY+16.0pp

QoQ-39.2pp

Protalix BioTherapeutics, Inc.'s operating margin was 23.5% in Q2 2026, reflecting core business profitability. This is up 16.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 39.2 percentage points.

Net Margin

19.0%

YoY+17.9pp

QoQ-35.3pp

Protalix BioTherapeutics, Inc.'s net profit margin was 19.0% in Q2 2026, showing the share of revenue converted to profit. This is up 17.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 35.3 percentage points.

Return on Equity

5.3%

YoY+5.0pp

QoQ-22.0pp

Protalix BioTherapeutics, Inc.'s ROE was 5.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 5.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 22.0 percentage points.

Capital Allocation

R&D Spending

$4.4M

YoY-27.4%

QoQ-19.8%

5Y CAGR-10.8%

10Y CAGR-8.0%

Protalix BioTherapeutics, Inc. invested $4.4M in research and development in Q2 2026. This represents a decrease of 27.4% from the same quarter a year earlier. Against the prior quarter it is down 19.8%.

Capital Expenditures

$593K

YoY+37.6%

QoQ-22.1%

5Y CAGR+16.1%

10Y CAGR+6.2%

Protalix BioTherapeutics, Inc. invested $593K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 37.6% from the same quarter a year earlier. Against the prior quarter it is down 22.1%.

Share Buybacks

Not reported for Q2 2026.

PLX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PLX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$80.6M	$52.7M-1.2%	$53.4M-18.5%	$65.5M+37.5%	$47.6M+24.2%	$38.4M-39.0%	$62.9M+15.0%	$54.7M+59.7%	$34.2M+62.4%	$21.1M+129.1%	$9.2M+110.8%	$4.4M+23.9%	$3.5M-40.4%	$5.9M-83.0%	$34.9M+315.8%	$8.4M
Cost of Revenue	$24.8M	$27.0M+11.0%	$24.3M+5.8%	$23.0M+17.3%	$19.6M+19.8%	$16.3M+50.4%	$10.9M-0.2%	$10.9M+17.1%	$9.3M-38.9%	$15.2M+81.4%	$8.4M+1050.4%	$730K+15.9%	$630K	$0-100.0%	$8.1M+434.0%	$1.5M
Gross Profit	$55.8M	$25.8M-11.4%	$29.1M-31.6%	$42.5M+51.6%	$28.0M+27.5%	$22.0M-57.7%	$52.0M+18.8%	$43.8M+75.6%	$24.9M+521.7%	$4.0M+400.7%	$801K-78.0%	$3.6M+25.6%	$2.9M	$0-100.0%	$26.3M+1721.2%	$1.4M
R&D Expenses	$19.9M	$19.6M+50.9%	$13.0M-24.1%	$17.1M-41.8%	$29.3M-1.3%	$29.7M-22.1%	$38.2M-14.5%	$44.6M+33.9%	$33.3M+3.6%	$32.2M+5.8%	$30.4M+22.2%	$24.9M-9.0%	$27.4M-6.4%	$29.2M-20.3%	$36.7M-3.0%	$37.8M
SG&A Expenses	$12.6M	$11.7M-4.2%	$12.2M-18.5%	$15.0M+27.7%	$11.7M-8.0%	$12.7M+14.2%	$11.1M+12.6%	$9.9M-9.3%	$10.9M-5.3%	$11.5M+23.2%	$9.4M+28.5%	$7.3M-21.1%	$9.2M+14.6%	$8.1M-17.5%	$9.8M+40.9%	$6.9M
Operating Income	$23.3M	-$5.5M-240.4%	$3.9M-62.6%	$10.5M+180.4%	-$13.0M+36.4%	-$20.5M-855.1%	$2.7M+125.3%	-$10.7M+44.5%	-$19.3M+44.1%	-$34.5M-4.1%	-$33.2M-40.1%	-$23.7M+17.1%	-$28.6M+16.2%	-$34.1M-179.8%	-$12.2M+66.7%	-$36.5M
EBITDA	N/A	-$4.0M-177.3%	$5.2M-55.2%	$11.7M+197.7%	-$11.9M+38.3%	-$19.3M-582.2%	$4.0M+144.1%	-$9.1M+48.4%	-$17.6M+45.9%	-$32.6M-4.5%	-$31.2M-46.4%	-$21.3M+16.2%	-$25.4M+16.7%	-$30.5M-260.0%	-$8.5M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$3.5M0.0%	$3.5M+249.7%	$1.0M	N/A	N/A
Income Tax	$4.5M	$996K-18.5%	$1.2M+381.1%	$254K-52.1%	$530K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$18.9M	-$6.6M-325.2%	$2.9M-64.7%	$8.3M+155.7%	-$14.9M+45.9%	-$27.6M-322.8%	-$6.5M+64.3%	-$18.3M+30.9%	-$26.5M+68.3%	-$83.4M-184.1%	-$29.4M-150.6%	$58.0M+293.8%	-$29.9M-7.7%	-$27.8M-139.2%	-$11.6M+68.2%	-$36.5M
EPS (Basic)	N/A	-$0.08-300.0%	$0.04-66.7%	$0.12+138.7%	-$0.31+50.0%	-$0.62-181.8%	-$0.22+82.1%	-$1.23	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$0.23	-$0.08-300.0%	$0.04-55.6%	$0.09	-$0.31+50.0%	-$0.62	-$0.22	-$1.23	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	79M-3.1%	81M-1.7%	82M	48M+9.8%	44M	29M	15M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$19.9M+27.1%	$33.8M+233.7%	$9.1M-49.9%	$17.9M-0.6%	$15.7M+16.2%	$10.1M+169.8%	$18.2M+73.7%	$18.0M+73.6%
Cost of Revenue	$7.8M+32.2%	$4.1M-49.5%	$4.6M+18.9%	$8.3M-0.6%	$5.9M-37.9%	$8.2M+214.4%	$3.9M-56.1%	$8.4M+71.2%
Gross Profit	$12.1M+24.0%	$29.6M+1432.5%	$4.5M-68.6%	$9.5M-0.6%	$9.8M+143.6%	$1.9M+68.7%	$14.3M+779.3%	$9.6M+75.8%
R&D Expenses	$4.4M-27.4%	$5.4M+56.1%	$5.6M+36.6%	$4.5M+49.0%	$6.0M+102.4%	$3.5M+20.4%	$4.1M+32.9%	$3.0M-18.3%
SG&A Expenses	$3.1M+18.6%	$3.1M+17.2%	$3.5M+17.6%	$2.9M+12.9%	$2.6M-24.7%	$2.6M-16.4%	$3.0M-27.6%	$2.6M-29.3%
Operating Income	$4.7M+298.6%	$21.1M+610.2%	-$4.7M-164.6%	$2.1M-46.6%	$1.2M+148.3%	-$4.1M+14.6%	$7.2M+228.4%	$4.0M+311.5%
EBITDA	$5.1M+231.5%	$21.6M+667.3%	-$4.3M-156.6%	$2.5M-42.1%	$1.5M+172.7%	-$3.8M+16.2%	$7.5M+242.3%	$4.3M+373.1%
Income Tax	$1.1M+117.9%	$2.8M+2599.1%	$728K-11.4%	-$116K-119.1%	$497K+820.3%	-$113K+18.1%	$822K+315.2%	$607K+356.4%
Net Income	$3.8M+2203.0%	$18.3M+606.1%	-$5.5M-184.8%	$2.4M-27.2%	$164K+107.4%	-$3.6M+21.2%	$6.5M+207.4%	$3.2M+274.7%
EPS (Basic)	$0.05	$0.23+560.0%	-$0.07-177.8%	$0.03-25.0%	$0.00+100.0%	-$0.05+16.7%	$0.09+190.0%	$0.04+233.3%
EPS (Diluted)	$0.05	$0.22+540.0%	-$0.07-177.8%	$0.030.0%	$0.00+100.0%	-$0.05+16.7%	$0.09+228.6%	$0.03
Diluted Shares (Avg)	83M+1.6%	83M+8.4%	N/A	81M-0.5%	81M+10.9%	77M+4.9%	N/A	81M

Not reported in any period shown, so not listed: Interest Expense.

PLX Balance Sheet

PLX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$82.3M+12.2%	$73.4M-13.0%	$84.4M+51.4%	$55.8M-24.3%	$73.7M+8.4%	$67.9M+49.7%	$45.4M-25.7%	$61.1M-15.3%	$72.2M-12.2%	$82.2M-15.4%	$97.3M+24.1%	$78.4M-30.9%	$113.3M+44.0%	$78.7M+52.0%	$51.8M
Current Assets	$66.7M+11.0%	$60.1M-14.1%	$69.9M+55.8%	$44.9M-27.2%	$61.7M+10.7%	$55.7M+71.6%	$32.5M-38.7%	$53.0M-15.4%	$62.7M-12.8%	$71.9M-16.3%	$85.9M+31.1%	$65.5M-33.1%	$97.9M+60.1%	$61.2M+88.3%	$32.5M
Cash & Equivalents	$14.7M-25.7%	$19.8M-16.4%	$23.6M+38.1%	$17.1M-56.1%	$39.0M+113.4%	$18.3M+2.7%	$17.8M-52.9%	$37.8M-26.1%	$51.2M-19.1%	$63.3M-17.1%	$76.4M+39.5%	$54.8M-36.6%	$86.4M+66.0%	$52.0M+92.7%	$27.0M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$25.7M+21.1%	$21.2M+11.5%	$19.0M+13.3%	$16.8M-6.4%	$18.0M+37.2%	$13.1M+60.4%	$8.2M-4.8%	$8.6M+9.4%	$7.8M+49.3%	$5.2M-9.1%	$5.8M+67.1%	$3.5M-56.6%	$8.0M+97.0%	$4.0M+1347.7%	$279K
Accounts Receivable	$8.8M+203.9%	$2.9M-44.8%	$5.3M+15.0%	$4.6M+33.2%	$3.4M+72.1%	$2.0M-57.4%	$4.7M-0.6%	$4.7M+174.8%	$1.7M+148.3%	$693K	$0-100.0%	$1.9M-9.9%	$2.1M+48.3%	$1.4M+2.6%	$1.4M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$34.1M+12.9%	$30.2M-40.6%	$50.9M-23.4%	$66.4M-16.7%	$79.7M-16.1%	$95.0M-17.9%	$115.7M+1.5%	$114.0M+12.1%	$101.7M+10.3%	$92.2M+6.7%	$86.4M-35.5%	$134.0M-4.5%	$140.3M+70.9%	$82.1M+5.4%	$77.9M
Current Liabilities	$26.5M+3.5%	$25.6M-43.7%	$45.5M+40.4%	$32.4M-2.3%	$33.2M-61.6%	$86.5M+115.2%	$40.2M+58.5%	$25.4M+11.4%	$22.8M-65.6%	$66.2M+489.3%	$11.2M-82.5%	$64.4M+141.1%	$26.7M+3.7%	$25.8M+37.8%	$18.7M
Non-Current Liabilities	$7.6M+65.7%	$4.6M-14.1%	$5.3M-84.3%	$34.0M-26.9%	$46.5M+447.5%	$8.5M-88.8%	$75.5M-14.8%	$88.7M+12.3%	$78.9M+203.6%	$26.0M-65.4%	$75.1M+8.0%	$69.6M-38.7%	$113.6M+101.6%	$56.3M-4.8%	$59.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$912K-61.5%	$2.4M-56.3%	$5.4M-17.4%	$6.6M
Total Equity	$48.2M+11.6%	$43.2M+28.7%	$33.6M+415.5%	-$10.6M-76.3%	-$6.0M+77.7%	-$27.0M+61.6%	-$70.3M-33.0%	-$52.9M-79.5%	-$29.5M-195.8%	-$10.0M-191.6%	$10.9M+119.6%	-$55.6M-106.3%	-$26.9M-702.7%	-$3.4M+87.1%	-$26.1M
Retained Earnings	-$385.0M-1.7%	-$378.4M+0.8%	-$381.5M+2.1%	-$389.9M-4.0%	-$374.9M-7.9%	-$347.4M-1.9%	-$340.8M-5.7%	-$322.6M-8.9%	-$296.1M-39.2%	-$212.7M-16.0%	-$183.3M+24.0%	-$241.3M-14.2%	-$211.4M-15.1%	-$183.6M-6.8%	-$172.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$110.3M+40.6%	$102.3M+38.5%	$82.3M+12.2%	$82.3M+33.6%	$78.5M-14.3%	$73.9M-17.7%	$73.4M-13.0%	$61.6M-29.7%
Current Assets	$92.2M+40.8%	$86.4M+42.7%	$66.7M+11.0%	$66.5M+39.0%	$65.5M-15.4%	$60.5M-19.7%	$60.1M-14.1%	$47.9M-34.1%
Cash & Equivalents	$27.4M+53.2%	$41.0M+110.7%	$14.7M-25.7%	$13.6M-50.2%	$17.9M-23.5%	$19.5M-28.5%	$19.8M-16.4%	$27.4M+34.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$32.3M+52.8%	$30.5M+56.2%	$25.7M+21.1%	$21.3M+23.6%	$21.1M+2.0%	$19.5M-12.7%	$21.2M+11.5%	$17.2M-20.3%
Accounts Receivable	$16.5M+74.8%	$2.9M-37.1%	$8.8M+203.9%	$14.4M+557.2%	$9.4M-6.7%	$4.7M+24.4%	$2.9M-44.8%	$2.2M-75.4%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$38.9M+36.2%	$35.1M+22.4%	$34.1M+12.9%	$29.4M+0.8%	$28.6M-54.6%	$28.7M-52.2%	$30.2M-40.6%	$29.1M-40.9%
Current Liabilities	$31.4M+30.3%	$27.4M+12.6%	$26.5M+3.5%	$21.9M-9.4%	$24.1M-58.4%	$24.3M-55.6%	$25.6M-43.7%	$24.2M-44.1%
Non-Current Liabilities	$7.5M+67.9%	$7.7M+77.0%	$7.6M+65.7%	$7.4M+51.1%	$4.5M-9.9%	$4.4M-16.3%	$4.6M-14.1%	$4.9M-17.7%
Total Equity	$71.4M+43.1%	$67.2M+48.7%	$48.2M+11.6%	$52.9M+63.1%	$49.9M+74.6%	$45.2M+51.8%	$43.2M+28.7%	$32.4M-15.2%
Retained Earnings	N/A	N/A	-$385.0M-1.7%	N/A	N/A	N/A	-$378.4M+0.8%	N/A

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

PLX Cash Flow Statement

PLX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$9.9M	-$12.0M-238.3%	$8.7M+758.1%	-$1.3M+94.7%	-$25.0M-143.1%	-$10.3M+60.6%	-$26.1M-34.9%	-$19.4M-150.0%	-$7.7M+22.5%	-$10.0M+68.9%	-$32.1M-32.2%	-$24.3M+17.1%	-$29.3M+4.5%	-$30.7M-4927.2%	$635K+102.7%	-$23.6M
Depreciation & Amortization	N/A	$1.5M+12.3%	$1.3M+9.5%	$1.2M+9.7%	$1.1M-2.9%	$1.1M-14.1%	$1.3M-19.5%	$1.6M-3.2%	$1.7M-13.0%	$1.9M-3.2%	$2.0M-16.3%	$2.4M-24.5%	$3.1M-11.3%	$3.5M-4.1%	$3.7M	N/A
Stock-Based Compensation	N/A	$2.3M-29.4%	$3.3M-5.7%	$3.4M+65.4%	$2.1M-12.2%	$2.4M-24.0%	$3.1M+274.4%	$835K+62.5%	$514K+52.5%	$337K-65.9%	$988K-45.2%	$1.8M+45.1%	$1.2M-69.6%	$4.1M-47.2%	$7.8M+774.8%	$886K
Capital Expenditures	$2.3M	$1.6M+27.8%	$1.3M+11.6%	$1.1M+83.0%	$628K-57.0%	$1.5M+122.7%	$655K+4.5%	$627K-8.6%	$686K-29.4%	$971K+14.4%	$849K+83.0%	$464K-40.9%	$785K-58.5%	$1.9M-8.6%	$2.1M-63.8%	$5.7M
Free Cash Flow	$7.7M	-$13.6M-284.4%	$7.4M+399.6%	-$2.5M+90.4%	-$25.6M-118.2%	-$11.7M+56.1%	-$26.8M-33.9%	-$20.0M-137.1%	-$8.4M+23.1%	-$11.0M+66.7%	-$32.9M-33.1%	-$24.7M+17.7%	-$30.1M+7.6%	-$32.5M-2171.0%	-$1.4M+95.1%	-$29.3M
Investing Cash Flow	-$1.0M	-$2.4M-156.1%	$4.2M+125.3%	-$16.7M-231.9%	-$5.0M-126.6%	$18.9M+194.8%	-$20.0M-2159.6%	-$883K-49.4%	-$591K+47.2%	-$1.1M-15.7%	-$967K-102.5%	$39.4M+4034.8%	-$1.0M+52.4%	-$2.1M+8.0%	-$2.3M+61.0%	-$5.9M
Financing Cash Flow	$296K	$9.3M+155.5%	-$16.8M-168.1%	$24.7M+199.4%	$8.2M-31.8%	$12.1M-74.0%	$46.5M	$0+100.0%	-$4.8M-234.9%	-$1.4M-107.2%	$19.7M+196.8%	$6.6M	N/A	N/A	$26.6M+26.9%	$20.9M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$10.4M-98.7%	$22.0M+535.4%	$2.0M-49.1%	-$3.7M-190.9%	-$5.2M-45.0%	-$5.1M-220.8%	$4.0M+11.0%	$4.1M+159.6%
Depreciation & Amortization	$406K+12.8%	$404K+16.8%	$387K+15.9%	$372K+13.1%	$360K+12.9%	$346K+7.5%	$334K+6.7%	$329K+7.9%
Stock-Based Compensation	N/A	$532K-1.5%	N/A	N/A	N/A	$540K-45.0%	N/A	N/A
Capital Expenditures	$593K+37.6%	$761K+148.7%	$403K-5.2%	$498K+472.4%	$431K+150.6%	$306K-48.8%	$425K+70.0%	$87K-80.5%
Free Cash Flow	-$11.0M-94.1%	$21.3M+496.4%	$1.6M-54.4%	-$4.2M-205.3%	-$5.7M-49.8%	-$5.4M-249.4%	$3.6M+6.6%	$4.0M+154.8%
Investing Cash Flow	-$3.6M-729.9%	$4.2M+1453.5%	-$1.1M+92.7%	-$504K-102.5%	-$438K-143.3%	-$312K+48.5%	-$15.3M-4379.5%	$20.3M+197.4%
Financing Cash Flow	$0-100.0%	$150K-97.0%	$146K-96.0%	$0	$4.1M	$5.1M	$3.6M	N/A

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PLX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PLX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	48.8%-5.6pp	54.5%-10.5pp	64.9%+6.0pp	58.9%+1.5pp	57.4%-25.3pp	82.7%+2.6pp	80.1%+7.3pp	72.8%+53.8pp	19.0%+10.3pp	8.7%-74.6pp	83.3%+1.1pp	82.1%+82.1pp	0.0%-75.4pp	75.4%+58.2pp	17.2%
Operating Margin	-10.4%-17.8pp	7.3%-8.6pp	16.0%+43.3pp	-27.3%+26.0pp	-53.4%-57.7pp	4.3%+23.9pp	-19.6%+36.8pp	-56.4%	-163.8%	-360.5%	-542.4%	-810.6%	-575.8%	-34.9%	-435.6%
Net Margin	-12.5%-18.0pp	5.5%-7.2pp	12.7%+44.0pp	-31.3%+40.6pp	-71.9%-61.5pp	-10.4%+23.0pp	-33.4%+43.9pp	-77.3%	-395.9%	-319.2%	1329.9%	-849.9%	-469.7%	-33.3%	-435.6%
Return on Equity	-13.7%-20.5pp	6.8%-18.0pp	24.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	533.8%	N/A	N/A	N/A	N/A
Return on Assets	-8.0%-12.0pp	4.0%-5.9pp	9.8%+36.6pp	-26.8%+10.7pp	-37.4%-27.8pp	-9.6%+30.7pp	-40.3%+3.0pp	-43.3%+72.3pp	-115.5%-79.8pp	-35.7%-95.4pp	59.7%+97.9pp	-38.2%-13.7pp	-24.5%-9.8pp	-14.8%+55.7pp	-70.5%
Current Ratio	2.51+0.2x	2.34+0.8x	1.54+0.2x	1.38-0.5x	1.86+1.2x	0.64-0.2x	0.81-1.3x	2.09-0.7x	2.75+1.7x	1.09-6.6x	7.64+6.6x	1.02-2.6x	3.67+1.3x	2.38+0.6x	1.74
Debt-to-Equity	0.710.0x	0.70-0.8x	1.52	N/A	N/A	N/A	N/A	N/A	N/A	N/A	7.94	N/A	N/A	N/A	N/A
Asset Turnover	0.64-0.1x	0.730.0x	0.78-0.1x	0.85+0.3x	0.52-0.4x	0.93-0.3x	1.20+0.6x	0.56+0.3x	0.29+0.2x	0.11+0.1x	0.040.0x	0.040.0x	0.05-0.4x	0.44+0.3x	0.16
FCF Margin	-25.8%-39.7pp	13.8%+17.6pp	-3.8%+50.0pp	-53.8%-23.2pp	-30.6%+11.9pp	-42.5%-6.0pp	-36.5%-11.9pp	-24.6%+27.4pp	-52.0%	-358.2%	-567.1%	-853.4%	-550.1%	-4.1%	-349.1%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	61.0%-1.5pp	87.8%+68.7pp	49.4%-29.3pp	53.4%0.0pp	62.5%+32.7pp	19.1%-11.5pp	78.7%+63.1pp	53.4%+0.7pp
Operating Margin	23.5%+16.0pp	62.6%+103.6pp	-51.1%-90.6pp	11.9%-10.3pp	7.5%+25.5pp	-41.0%	39.6%+93.1pp	22.2%+40.5pp
Net Margin	19.0%+17.9pp	54.3%+90.1pp	-60.3%-96.0pp	13.2%-4.8pp	1.1%+17.4pp	-35.8%	35.6%+93.3pp	18.0%+35.9pp
Return on Equity	5.3%+5.0pp	27.3%+35.3pp	-11.4%-26.4pp	4.5%-5.5pp	0.3%+8.0pp	-8.0%+7.4pp	15.0%+33.0pp	10.0%+14.8pp
Return on Assets	3.4%+3.2pp	17.9%+22.8pp	-6.7%-15.5pp	2.9%-2.4pp	0.2%+2.6pp	-4.9%+0.2pp	8.8%+16.0pp	5.3%+7.4pp
Current Ratio	2.94+0.2x	3.15+0.7x	2.51+0.2x	3.03+1.1x	2.72+1.4x	2.49+1.1x	2.34+0.8x	1.98+0.3x
Debt-to-Equity	0.550.0x	0.52-0.1x	0.710.0x	0.55-0.3x	0.57-1.6x	0.63-1.4x	0.70-0.8x	0.90-0.4x
Asset Turnover	0.180.0x	0.33+0.2x	0.11-0.1x	0.22-0.1x	0.20+0.1x	0.14+0.1x	0.25+0.1x	0.29+0.2x
FCF Margin	-55.3%-19.1pp	63.0%+116.0pp	17.8%-1.7pp	-23.7%-46.1pp	-36.2%-8.1pp	-53.0%-148.8pp	19.6%-12.3pp	22.4%+93.3pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Protalix BioTherapeutics, Inc. PLX	FY2025	$52.7M	-$6.6M	-12.5%	$224.0M	39/100
Inovio Pharmaceuticals, Inc. INO	FY2025	$65K	-$85.0M	N/A	$118.9M	—
Avalo Therapeutics, Inc. AVTX	FY2025	$59K	-$78.3M	N/A	$732.0M	—
Orchestra BioMed Holdings, Inc. OBIO	FY2025	$33.5M	-$52.7M	N/A	$357.6M	63/100
SANGAMO THERAPEUTICS INC SGMO	FY2025	$39.6M	-$122.9M	N/A	$55.9M	—
Seres Therapeutics, Inc. MCRB	FY2025	$789K	$5.7M	N/A	$27.2M	—

Where Protalix BioTherapeutics, Inc. Ranks

Frequently Asked Questions

What is Protalix BioTherapeutics, Inc.'s annual revenue?

Protalix BioTherapeutics, Inc. (PLX) reported $52.7M in total revenue for fiscal year 2025. This represents a -1.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Protalix BioTherapeutics, Inc.'s revenue growing?

Protalix BioTherapeutics, Inc. (PLX) revenue declined by 1.2% year-over-year, from $53.4M to $52.7M in fiscal year 2025.

Is Protalix BioTherapeutics, Inc. profitable?

No, Protalix BioTherapeutics, Inc. (PLX) reported a net income of -$6.6M in fiscal year 2025, with a net profit margin of -12.5%.

What is Protalix BioTherapeutics, Inc.'s EBITDA?

Protalix BioTherapeutics, Inc. (PLX) had EBITDA of -$4.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Protalix BioTherapeutics, Inc.'s gross margin?

Protalix BioTherapeutics, Inc. (PLX) had a gross margin of 48.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Protalix BioTherapeutics, Inc.'s operating margin?

Protalix BioTherapeutics, Inc. (PLX) had an operating margin of -10.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Protalix BioTherapeutics, Inc.'s net profit margin?

Protalix BioTherapeutics, Inc. (PLX) had a net profit margin of -12.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Protalix BioTherapeutics, Inc.'s return on equity (ROE)?

Protalix BioTherapeutics, Inc. (PLX) has a return on equity of -13.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Protalix BioTherapeutics, Inc.'s free cash flow?

Protalix BioTherapeutics, Inc. (PLX) recorded an outflow of $13.6M in free cash flow during fiscal year 2025. This represents a -284.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Protalix BioTherapeutics, Inc.'s operating cash flow?

Protalix BioTherapeutics, Inc. (PLX) recorded an outflow of $12.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Protalix BioTherapeutics, Inc.'s total assets?

Protalix BioTherapeutics, Inc. (PLX) had $82.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Protalix BioTherapeutics, Inc.'s capital expenditures?

Protalix BioTherapeutics, Inc. (PLX) invested $1.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Protalix BioTherapeutics, Inc. spend on research and development?

Protalix BioTherapeutics, Inc. (PLX) invested $19.6M in research and development during fiscal year 2025.

How many shares does Protalix BioTherapeutics, Inc. have outstanding?

Protalix BioTherapeutics, Inc. (PLX) had 81M shares outstanding as of fiscal year 2025.

What is Protalix BioTherapeutics, Inc.'s current ratio?

Protalix BioTherapeutics, Inc. (PLX) had a current ratio of 2.51 as of fiscal year 2025, which is generally considered healthy.

What is Protalix BioTherapeutics, Inc.'s debt-to-equity ratio?

Protalix BioTherapeutics, Inc. (PLX) had a debt-to-equity ratio of 0.71 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Protalix BioTherapeutics, Inc.'s return on assets (ROA)?

Protalix BioTherapeutics, Inc. (PLX) had a return on assets of -8.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Protalix BioTherapeutics, Inc.'s P/E ratio?

Protalix BioTherapeutics, Inc. (PLX) trades at 11.8x earnings, its market capitalization divided by net income of $18.9M net income, trailing 12 months to June 30, 2026. The market capitalization is $224.0M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Protalix BioTherapeutics, Inc.'s price-to-sales ratio?

Protalix BioTherapeutics, Inc. (PLX) trades at 2.8x sales, its market capitalization divided by revenue of $80.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $224.0M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Protalix BioTherapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Protalix BioTherapeutics, Inc. (PLX) held $14.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $12.0M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Protalix BioTherapeutics, Inc.'s Altman Z-Score?

Protalix BioTherapeutics, Inc. (PLX) has an Altman Z-Score of -1.60, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Protalix BioTherapeutics, Inc.'s Piotroski F-Score?

Protalix BioTherapeutics, Inc. (PLX) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Protalix BioTherapeutics, Inc.'s earnings high quality?

Protalix BioTherapeutics, Inc. (PLX) reported a net loss of $6.6M while operations used $12.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Protalix BioTherapeutics, Inc.?

Protalix BioTherapeutics, Inc. (PLX) scores 39 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.